ERBB2 and neoplasm: Primary tumours which were HER2-low at diagnosis represented just under a half of the entire study sample (44.9%), followed by HER2-negative tumours (39.3%) and HER2-positive tumours (15.8%), which is concordant with the data reported in the literature [8, 19, 20].